Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 2/20 | 0.58 |
| ▸ | TK1 | P04183 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
| ▸ | TK2 | O00142 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL658758 | 1.00 | CDA (0.58) | CDATK1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL6015192 | 1.00 | CDA (0.58) | CDATK1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL15893325 | 1.00 | CDA (0.58) | CDATK1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL21423103 | 1.00 | CDA (0.58) | CDATK1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL4318242 | 1.00 | CDA (0.58) | CDATK1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL15895803 | 1.00 | CDA (0.58) | CDATK1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL31685506 | 0.81 | TYMS (0.48) | — | |
| SCHEMBL22916929 | 0.79 | CDA (0.44) | CDATK1TSHR | |
| SCHEMBL23240762 | 0.78 | CDA (0.58) | CDATK1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL172249 | 0.78 | CDA (0.58) | CDATK1LMNASMN1; SMN2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | claimed |
| US-8252768-B2 | Designer therapy of pancreatic tumors | UNIVERSITY OF MIAMI (US) | 2012-08-28 | — | — | US | claimed |
| US-8158770-B2 | Content dependent inhibitors of cytidine deaminases and uses thereof | UNIVERSITY OF ROCHESTER (US) | 2012-04-17 | — | — | US | claimed |
| US-7776838-B1 | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-08-17 | — | — | US | claimed |
| US-20090325897-A1 | DESIGNER THERAPY OF PANCREATIC TUMORS | UNIVERSITY OF MIAMI (US) | 2009-12-31 | — | — | US | claimed |
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | claimed |
| US-20090075342-A1 | Metabolic profile directed aptamer medicinal chemistry | ARCHEMIX CORP. | 2009-03-19 | — | — | US | claimed |
| WO-2008134077-A1 | METABOLIC PROFILE DIRECTED APTAMER MEDICINAL CHEMISTRY | ARCHEMIX CORP. (US) | 2008-11-06 | — | — | WO | claimed |
| WO-2008085611-A2 | DESIGNER THERAPHY OF PANCREATIC TUMORS | UNIVERSITY OF MIAMI (US) | 2008-07-17 | — | — | WO | claimed |
| JP-2008512097-A | — | — | 2008-04-24 | — | — | JP | claimed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | claimed |
| US-4990499-A | Treatment of infections and neoplasms | UNIVERSITY OF SASKATCHEWAN (CA) | 1991-02-05 | — | — | US | claimed |
| EP-0160079-B1 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION | GREER, Sheldon B. (US) | 1990-01-31 | — | — | EP | claimed |
| US-4894364-A | ANTITUMOR AGENTS | HALOGENETICS, INC. | 1990-01-16 | — | — | US | claimed |
| EP-0258412-A1 | COMPOSITION FOR AND METHOD OF TREATING AIDS AND CERTAIN RELATED DISEASES | GREER, Sheldon B. (US) | 1988-03-09 | — | — | EP | claimed |
| WO-1987004929-A1 | COMPOSITION FOR AND METHOD OF TREATING AIDS AND CERTAIN RELATED DISEASES | GREER SHELDON B | 1987-08-27 | — | — | WO | claimed |
| EP-0160079-A4 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION. | GREER SHELDON B | 1986-05-14 | — | — | EP | claimed |
| EP-0160079-A1 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION. | GREER SHELDON B | 1985-11-06 | — | — | EP | claimed |
| WO-1985001871-A1 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION | GREER SHELDON B | 1985-05-09 | — | — | WO | claimed |
| US-4210638-A | 5-TRIFLUOROMETHYL-2'-DEOXYCYCTIDINE AND TETRAHYDROURIDINE OR 2'-DEOXYTETRAHYDROURIDINE | PCR, INC. (US) | 1980-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | DCTD, CDA, ADA | CDA 2/4885TK1 178/4885LMNA 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.